CN103370083B - 具有增强的作用持续时间的工程化多肽 - Google Patents

具有增强的作用持续时间的工程化多肽 Download PDF

Info

Publication number
CN103370083B
CN103370083B CN201180057092.1A CN201180057092A CN103370083B CN 103370083 B CN103370083 B CN 103370083B CN 201180057092 A CN201180057092 A CN 201180057092A CN 103370083 B CN103370083 B CN 103370083B
Authority
CN
China
Prior art keywords
seq
exendin
compound
engineered
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180057092.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103370083A (zh
Inventor
M.埃里克森
D.C.利特辛格
S.S.戈什
Z.郭
S.内拉维特拉
L.马梅多瓦
O.E.利维
C.J.索雷斯
M.P.萨曼特
C.孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44786115&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103370083(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Priority to CN201610892824.3A priority Critical patent/CN106986940A/zh
Publication of CN103370083A publication Critical patent/CN103370083A/zh
Application granted granted Critical
Publication of CN103370083B publication Critical patent/CN103370083B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
CN201180057092.1A 2010-09-28 2011-09-28 具有增强的作用持续时间的工程化多肽 Expired - Fee Related CN103370083B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610892824.3A CN106986940A (zh) 2010-09-28 2011-09-28 具有增强的作用持续时间的工程化多肽

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38739110P 2010-09-28 2010-09-28
US61/387,391 2010-09-28
US42208510P 2010-12-10 2010-12-10
US61/422,085 2010-12-10
PCT/US2011/053770 WO2012050923A2 (en) 2010-09-28 2011-09-28 Engineered polypeptides having enhanced duration of action

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610892824.3A Division CN106986940A (zh) 2010-09-28 2011-09-28 具有增强的作用持续时间的工程化多肽

Publications (2)

Publication Number Publication Date
CN103370083A CN103370083A (zh) 2013-10-23
CN103370083B true CN103370083B (zh) 2016-11-16

Family

ID=44786115

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180057092.1A Expired - Fee Related CN103370083B (zh) 2010-09-28 2011-09-28 具有增强的作用持续时间的工程化多肽
CN201610892824.3A Pending CN106986940A (zh) 2010-09-28 2011-09-28 具有增强的作用持续时间的工程化多肽

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610892824.3A Pending CN106986940A (zh) 2010-09-28 2011-09-28 具有增强的作用持续时间的工程化多肽

Country Status (11)

Country Link
US (2) US9593154B2 (enExample)
EP (2) EP2621538B1 (enExample)
JP (1) JP6121330B2 (enExample)
CN (2) CN103370083B (enExample)
BR (1) BR112013007442A2 (enExample)
CA (1) CA2812951A1 (enExample)
EA (1) EA201390450A1 (enExample)
ES (1) ES2563091T3 (enExample)
HK (1) HK1225307A1 (enExample)
MX (1) MX345245B (enExample)
WO (1) WO2012050923A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
ES2563091T3 (es) * 2010-09-28 2016-03-10 Amylin Pharmaceuticals, Llc Polipéptidos modificados genéticamente que tienen duración de acción potenciada
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
EP2830665A1 (en) * 2012-03-28 2015-02-04 Affibody AB Oral administration
HK1208155A1 (en) * 2012-03-28 2016-02-26 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
RU2679889C2 (ru) 2013-04-18 2019-02-14 Армо Байосайенсиз, Инк. Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
WO2015031316A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN105848674A (zh) 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP7121496B2 (ja) 2015-05-28 2022-08-18 アルモ・バイオサイエンシーズ・インコーポレイテッド 癌治療で使用するためのペグ化インターロイキン－１０
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
WO2017053391A1 (en) 2015-09-22 2017-03-30 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
US10286079B2 (en) 2015-09-22 2019-05-14 The Regents Of The University Of California Modified cytotoxins and their therapeutic use
EP3374504B1 (en) * 2015-11-09 2025-03-19 CureVac SE Optimized nucleic acid molecules
JP7026044B2 (ja) 2015-12-23 2022-02-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 神経性状態および神経変性状態の治療としての長時間作用型ＧＬＰ－１ｒアゴニスト
AR107890A1 (es) * 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
KR20200135618A (ko) * 2019-05-23 2020-12-03 ㈜ 디앤디파마텍 폴리펩티드를 포함하는 비알코올성 지방간 질환의 예방 또는 치료용 약학 조성물
KR20230034356A (ko) * 2020-07-02 2023-03-09 사노피 활성이 감소된 glp-1r 효능제 펩티드
CN115925951B (zh) * 2022-11-30 2024-05-24 上海交通大学医学院附属仁济医院 Cd70特异性诊疗一体化分子影像探针的制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101765608A (zh) * 2007-07-31 2010-06-30 阿菲博迪公司 新组合物、方法及应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
FR2672128B1 (fr) 1991-01-28 1995-08-18 Cis Bio Int Procede de mesure de la luminescence emise dans un dosage par luminescence.
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
DE69831673C5 (de) 1997-01-07 2015-01-22 Amylin Pharmaceuticals, Llc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
ES2235336T3 (es) 1997-06-13 2005-07-01 Gryphon Therapeutics, Inc. Ligacion quimica nativa en fase solida de peptidos desprotegidos o protegidos en la cisteina n-terminal en solucion acuosa.
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
CA2309356C (en) 1997-11-14 2010-09-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
EP1066314B1 (en) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
CA2320371C (en) 1998-02-13 2012-01-17 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
BRPI0007820B8 (pt) 1999-01-14 2021-05-25 Amylin Pharmaceuticals Llc formulações farmacêuticas agonistas de exendina e seus usos
BRPI0007823A8 (pt) 1999-01-14 2017-03-21 Amylin Pharmaceuticals Inc Métodos de supressão do glucagon
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
WO2004035623A2 (en) 2002-10-02 2004-04-29 Zealand Pharma A/S Stabilized exendin-4 compounds
ES2345113T3 (es) 2004-02-11 2010-09-15 Amylin Pharmaceuticals, Inc. Peptidos de la familia amilina y metodos para su obtencion y utilizacion.
US7399744B2 (en) 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ES2677619T3 (es) * 2005-11-28 2018-08-03 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
US20070238669A1 (en) 2006-01-11 2007-10-11 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
JP2009538824A (ja) 2006-03-31 2009-11-12 アミリン・ファーマシューティカルズ，インコーポレイテッド 精神疾患及び障害治療用アミリン及びアミリンアゴニスト
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
BRPI0712559A2 (pt) 2006-05-26 2012-11-20 Amylin Pharmaceuticals Inc composiÇÕes e mÉtodos para o tratamento de insuficiÊncia cardÍaca congestiva
SG173332A1 (en) * 2006-08-01 2011-08-29 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP2009003340A (ja) 2007-06-25 2009-01-08 Oki Data Corp 画像形成装置
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CA2718480A1 (en) * 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
WO2009143014A1 (en) 2008-05-23 2009-11-26 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist bioassays
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
PE20120170A1 (es) * 2009-02-19 2012-03-21 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas
US8642544B2 (en) 2009-04-01 2014-02-04 Amylin Pharmaceuticals, Llc N-terminus conformationally constrained GLP-1 receptor agonist compounds
ES2563091T3 (es) 2010-09-28 2016-03-10 Amylin Pharmaceuticals, Llc Polipéptidos modificados genéticamente que tienen duración de acción potenciada
HK1208155A1 (en) * 2012-03-28 2016-02-26 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101765608A (zh) * 2007-07-31 2010-06-30 阿菲博迪公司 新组合物、方法及应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A Protease-Based Strategy for the Controlled Release of Therapeutic Peptides;Hongjian Li et al.;《Angew. Chem. Int. Ed.》;20100609;第49卷(第29期);第4930-4933页 *
Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson"s disease;Goran Bertilsson et al.;《Journal of Neuroscience Research》;20070905;第86卷(第2期);第326-338页 *
The Versatile MHC Class I-related FcRn Protects IgG and Albumin from Degradation：Implications for Development of New Diagnostics and Therapeutics;Jan Terje Andersen and Inger Sandlie;《Drug Metab. Pharmacokinet.》;20090825;第24卷(第4期);第318-332页 *

Also Published As

Publication number Publication date
ES2563091T3 (es) 2016-03-10
US20170114114A1 (en) 2017-04-27
MX2013003481A (es) 2013-10-25
EP2621538A2 (en) 2013-08-07
US20140107019A1 (en) 2014-04-17
EP2621538B1 (en) 2015-12-16
EP3028720A1 (en) 2016-06-08
CN103370083A (zh) 2013-10-23
BR112013007442A2 (pt) 2019-09-24
WO2012050923A2 (en) 2012-04-19
CN106986940A (zh) 2017-07-28
US9593154B2 (en) 2017-03-14
HK1188710A1 (zh) 2014-05-16
HK1225307A1 (en) 2017-09-08
JP6121330B2 (ja) 2017-04-26
EA201390450A1 (ru) 2013-07-30
MX345245B (es) 2017-01-23
CA2812951A1 (en) 2012-04-19
JP2013545724A (ja) 2013-12-26
WO2012050923A3 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
CN103370083B (zh) 具有增强的作用持续时间的工程化多肽
US9382304B2 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
JP6412183B2 (ja) 作用持続時間が増した改変ポリペプチド
US20150133373A1 (en) Transmucosal delivery of engineered polypeptides
CN103957926B (zh) 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
WO2013148871A1 (en) Engineered polypeptides
US20180344813A1 (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
HK1188710B (en) Engineered polypeptides having enhanced duration of action
HK1196624B (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
HK1196624A (en) Engineered polypeptides having enhanced duration of action with reduced immunogenicity
HK1196093B (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
HK1196093A (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161116

CF01 Termination of patent right due to non-payment of annual fee